Trial Profile
Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms EYLEA-PMS
- Sponsors Bayer
- 02 Feb 2023 Status changed from active, no longer recruiting to completed.
- 03 Jan 2023 Planned End Date changed from 30 Nov 2022 to 4 Jan 2023.
- 15 Nov 2022 Planned primary completion date changed from 30 Oct 2022 to 25 Nov 2022.